Inhalation of Low Molecular Weight Heparins as a prophylaxis to prevent SARS-CoV-2 infection

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:7 publications

Grant number: 114025008

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $634,490.21
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

    Pending
  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    Amsterdam UMC (location AMC)
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    Gender

  • Study Subject

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project description Existing drug prevents SARS-CoV-2 infection There is a very urgent need for SARS-CoV-2 preventive drugs to stop the COVID-19 pandemic. We have found that infection of cells with SARS-CoV-2 is blocked by the anti-clotting drug low molecular weight heparin. This drug blocks the binding of the virus to the cells, which greatly reduces or even prevents infection.In this project we will investigate whether inhalation of low molecular weight heparin can be used as a preventive drug against SARS-CoV-2. To this end, we have developed animal-free innovations to determine the effectiveness of the intervention and to unravel the mechanism of action of this drug.

Publicationslinked via Europe PMC

Last Updated:38 minutes ago

View all publications at Europe PMC

Control of complement-induced inflammatory responses to SARS-CoV-2 infection by anti-SARS-CoV-2 antibodies.

SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lectin receptor DC-SIGN.

Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery.

Antibodies against SARS-CoV-2 control complement-induced inflammatory responses to SARS-CoV-2

Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2.

SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs.

Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans.